Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty

N/ACompletedNCT00831714

Bayer19,076 enrolled

Overview

The main goal is to provide additional information to the risk-benefit assessment of the drug.

Study Type

OBSERVATIONAL

Enrollment

19,076

Conditions

Venous Thromboembolism

Interventions

Rivaroxaban (Xarelto, BAY59-7939)DRUG

Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made

Standard care treatment for VTE prophylaxisDRUG

Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female and male patients who will undergo elective hip or knee arthroplasty. Exclusion Criteria: * Exclusion criteria must be read in conjunction with the local product information.

Locations (42)

Unnamed facility

Many Locations, Australia

Outcomes

Primary Outcomes

Data collection on: Bleeding events reported as serious or non-serious adverse events; Symptomatic thromboembolic events (DVT, PE) reported as adverse events; Uncommon adverse events (incidence rate between 0.1 % and 1 %); All cause mortality

Time frame: During observation period of three months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.